Lab21 unveils new molecular analysis services at Greenville site, USA

Lab21, the global specialist in personalised medicine and clinical diagnostics, announced recently that routine analysis of clinical samples has begun from Lab21 Inc.’s new CLIA laboratory in Greenville, South Carolina, USA.

The first assays in the test menu include a new Human Papillomavirus (HPV) high risk and HPV 16 and 18 genotyping service. Using the Roche COBAS 4800 HPV genotyping test, Lab21 can identify high risk patients and differentiate those patients with HPV 16 and HPV 18 genotypes. This service launches concurrently with new guidelines for the prevention and early detection of cervical cancer which were recently issued by the American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Society for Clinical Pathology (ASCP).

Lab21 Inc is focused on the provision of molecular diagnostic testing services in oncology and infectious disease. Launch of these services will include KRAS, EGFR and BRAF mutation analysis, HIV viral resistance and tropism and viral load assays. This follows Lab21’s recent launch of the Clinical Genomics Center at ITOR, a hospital-based cancer research organisation located in Greenville, South Carolina. It is planned that through the partnership with ITOR, Lab21 will develop new companion diagnostic assays required to accompany new drug therapies.

Lab21